InspireMD (NYSE: NSPR) director receives 88,053 restricted shares grant

Rhea-AI Filing Summary

InspireMD, Inc. director Scott R. Ward reported an equity award of common stock. On January 14, 2026, he received 88,053 shares of common stock at a price of $0 per share, characterized as an acquisition. These shares are restricted stock that will vest on January 14, 2027, as long as he continues in service with the company through that date. Following this grant, he beneficially owns 147,846 shares of InspireMD common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ward Scott R.

(Last) (First) (Middle)

C/O INSPIREMD, INC.

6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)

MIAMI FL 33126

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/14/2026		A		88,053(1)	A	$0	147,846	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

Remarks:

Exhibit 24.1: Power of Attorney

	/s/ Michael Lawless, Attorney-in-Fact for Scott R. Ward	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did InspireMD (NSPR) disclose in this Form 4?

The filing shows that director Scott R. Ward acquired 88,053 shares of InspireMD common stock on January 14, 2026 in a reported acquisition transaction.

What type of shares did Scott R. Ward receive from InspireMD (NSPR)?

The shares are restricted common stock. According to the disclosure, they represent restricted stock that will vest on January 14, 2027, subject to his continued service.

Was there a purchase price for the shares reported in the InspireMD (NSPR) Form 4?

The transaction lists a price of $0 per share for the 88,053 common shares, which is typical for equity awards granted as compensation rather than open-market purchases.

When do the restricted shares reported for InspireMD (NSPR) vest?

The 88,053 restricted shares are scheduled to vest on January 14, 2027, referred to as the "One Year Grant Anniversary Date", contingent on Scott R. Ward’s continued service.

How many InspireMD (NSPR) shares does Scott R. Ward own after this transaction?

After the reported grant, Scott R. Ward beneficially owns 147,846 shares of InspireMD common stock, held with direct ownership as indicated in the filing.

What is Scott R. Ward’s role at InspireMD (NSPR)?

The filing identifies Scott R. Ward as a director of InspireMD, Inc. He is not listed as an officer or a 10% beneficial owner in this report.